- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05828511
Een Window of Opportunity-onderzoek om te leren of Linvoseltamab veilig is en goed wordt verdragen, en hoe goed het werkt bij deelnemers met recent gediagnosticeerd multipel myeloom die nog geen behandeling hebben gekregen. (LINKER-MM4)
Fase 1/2-studie van linvoseltamab (anti-BCMA X anti-CD3 bispecifiek antilichaam) bij niet eerder behandelde patiënten met symptomatisch multipel myeloom
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible).
The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM.
This study consists of 2 phases:
- In Phase 1 Parts A and B, the study drug will be given to participants to study the side effects of the study drug and to establish the regimen (initial doses and full dose) of the study drug to be given to participants in Phase 2.
- In Phase 1 Part C, the study drug will be given to participants to study the side effects when using different initial doses of the study drug.
- In Phase 2, the study drug will be given to more participants to continue to assess the side effects of the study drug and to evaluate the activity of the study drug to shrink the tumor (multiple myeloma) in participants with NDMM.
The study is looking at several research questions, including:
- What side effects may happen from taking linvoseltamab?
- What the right dosing regimen is for linvoseltamab?
- How many participants treated with linvoseltamab have improvement of their disease and for how long?
- The effects of linvoseltamab study treatment before and after transplant
- How much linvoseltamab is in the blood at different times?
- Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
Lille, Frankrijk, 59000
- CHU De Lille
-
Montpellier, Frankrijk, 342950
- Centre Hospitalier Universitaire (CHU) Montpellier
-
Paris, Frankrijk, 75010
- Hopital Saint Louis
-
Paris, Frankrijk, 75651
- University Hospitals Pitie Salpetriere - Charles Foix
-
-
Vienne
-
Poitiers, Vienne, Frankrijk, 86021
- Centre Hospitalier Universitaire (CHU) de Poitiers
-
-
Île-de-France Region
-
Antony, Île-de-France Region, Frankrijk, 92160
- Hopital Prive d'Antony
-
Paris, Île-de-France Region, Frankrijk, 75015
- Hopital Necker
-
Villejuif, Île-de-France Region, Frankrijk, 94800
- Gustave Roussy
-
-
-
-
-
Barcelona, Spanje, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Spanje, 08908
- Institut Catala dOncologia (ICO Hospitalet)
-
Madrid, Spanje, 28027
- Clinica Universidad de Navarra - Madrid
-
Madrid, Spanje, 28006
- Universitary Hospital La Princesa
-
Salamanca, Spanje, 37007
- Hospital Universitario de Salamanca
-
Valencia, Spanje, 46026
- Hospital Universitari i Politecnic La Fe
-
-
Barcelona
-
Badalona, Barcelona, Spanje, 08916
- Hospital Germans Trias i Pujol
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spanje, 28223
- Hospital Universitario Quiron Salud Madrid
-
-
Navarre
-
Pamplona, Navarre, Spanje, 31008
- Clinica Universidad de Navarra
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Spanje, 33011
- Hospital Universitario Central de Asturias
-
-
Valencia
-
Alicante, Valencia, Spanje, 03010
- Hospital General Universitario Doctor Balmis Alicante
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095
- University of California Los Angeles (UCLA)
-
Orange, California, Verenigde Staten, 92868
- UC Irvine Health
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80218
- Colorado Blood Cancer Institute/SCRI
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40207
- Norton Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48201
- Karmanos Cancer Institute
-
-
New Jersey
-
New Brunswick, New Jersey, Verenigde Staten, 08901
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Mineola, New York, Verenigde Staten, 11501
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island
-
New York, New York, Verenigde Staten, 10016
- Perlmutter Cancer Center
-
New York, New York, Verenigde Staten, 10032
- Columbia University _ New York Presbyterian
-
Stony Brook, New York, Verenigde Staten, 11794
- Stony Brook University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Levine Cancer Institute
-
Durham, North Carolina, Verenigde Staten, 27705
- Duke University Health System (DUHS)
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Confirmed diagnosis of symptomatic Multiple Myeloma (MM) by International Myeloma Working Group (IMWG) diagnosis criteria, as described in the protocol
- Response-evaluable myeloma, according to the 2016 IMWG response criteria, as defined in the protocol
- No prior therapy for MM, with the exception of prior emergent or palliative radiation and up to 1 month of single-agent corticosteroids, with washout periods as per the protocol
- Participants must have evidence of adequate bone marrow reserves and hepatic, renal and cardiac function as defined in the protocol
- Participants must be age <70 and have adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible. The specific thresholds for adequate organ function are as per institutional guidance.
Key Exclusion Criteria:
- Receiving any concurrent investigational agent with known or suspected activity against MM, or agents targeting the A proliferation-inducing ligand (APRIL)/ Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)/BCMA axis
- Known Central Nervous System (CNS) involvement with MM, known or suspected Progressive Multifocal Leukoencephalopathy (PML), a history of neurocognitive conditions, or CNS movement disorder, or history of seizure within 12 months prior to study enrollment
- Rapidly progressive symptomatic disease, (e.g. progressing renal failure or hypercalcemia not responsive to standard medical interventions), in urgent need of treatment with chemotherapy
- Diagnosis of non-secretory MM, active plasma cell leukemia primary light-chain (AL) amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or known POEMS syndrome (Plasma cell dyscrasia with polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Phase 1 cohorts
Linvoseltamab dose escalation (part A), dose expansion (part B), and evaluation of alternative step-up regimen (part C) for participants with NDMM who are treatment-naïve. |
Linvoseltamab will be administered by intravenous (IV) infusion
Andere namen:
|
|
Experimenteel: Phase 2 - transplant ineligible cohort
Transplant-ineligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen until disease progression as per protocol. |
Linvoseltamab will be administered by intravenous (IV) infusion
Andere namen:
|
|
Experimenteel: Phase 2 - transplant eligible cohort
Transplant-eligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen for a fixed duration of treatment as per protocol |
Linvoseltamab will be administered by intravenous (IV) infusion
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of Dose-Limiting Toxicities (DLTs)
Tijdsspanne: End of the Observation period; up to day 28
|
Phase 1 |
End of the Observation period; up to day 28
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of TEAEs
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of Adverse Events of Special Interest (AESIs)
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of AESIs
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria
Tijdsspanne: Up to 5 years
|
Phase 2 |
Up to 5 years
|
|
Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy
Tijdsspanne: Up to 5 years
|
Phase 2 Transplant-eligible cohort |
Up to 5 years
|
|
Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy
Tijdsspanne: Up to 5 years
|
Phase 2 Transplant-eligible cohort |
Up to 5 years
|
|
Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II
Tijdsspanne: Up to 5 years
|
Phase 2 Transplant-ineligible cohort |
Up to 5 years
|
|
Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II
Tijdsspanne: Up to 5 years
|
Phase 2 Transplant ineligible cohort |
Up to 5 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Concentrations of Linvoseltamab in serum
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 12 weeks
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 12 weeks
|
|
Concentrations of total soluble B-Cell Maturation Antigen (BCMA)
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 12 weeks
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 12 weeks
|
|
Incidence of Anti-Drug Antibodies (ADAs) to Linvoseltamab
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 30 days
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 30 days
|
|
Magnitude of ADAs to Linvoseltamab
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 30 days
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 30 days
|
|
Objective Response Rate (ORR) measured using the IMWG criteria
Tijdsspanne: Up to 5 years
|
Phase 1 |
Up to 5 years
|
|
Duration Of Response (DOR) measured using the IMWG criteria
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Progression-Free Survival (PFS) measured using the IMWG criteria
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Proportion of participants achieving MRD-negative status (at 10^-5) in participants with NDMM measured using the IMWG criteria
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of TEAEs
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of TEAEs
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of AESIs
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of AESIs
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
ORR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tijdsspanne: Up to 5 years
|
Phase 2 |
Up to 5 years
|
|
MRD-negative status of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
DOR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
PFS of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Overall Survival (OS) of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Time To Response (TTR) as measured using the IMWG criteria
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
ORR by risk levels
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
MRD-negative status by risk levels
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
DOR by risk levels
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
TTR by risk levels
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
PFS by risk levels
Tijdsspanne: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of MRD-negative status
Tijdsspanne: Up to 5 years
|
Phase 2 |
Up to 5 years
|
|
Cluster of Differentiation 34+ (CD34+) stem cell yield
Tijdsspanne: At cycle 4 of induction (each cycle is 28 days long)
|
Phase 2 Transplant-eligible cohort |
At cycle 4 of induction (each cycle is 28 days long)
|
|
Time to neutrophil engraftment
Tijdsspanne: Up to 100 days post-transplant
|
Phase 2 Transplant-eligible cohort |
Up to 100 days post-transplant
|
|
Time to platelet engraftment
Tijdsspanne: Up to 100 days post-transplant
|
Phase 2 Transplant-eligible cohort |
Up to 100 days post-transplant
|
|
PFS after ASCT followed by 3 cycles of linvoseltamab
Tijdsspanne: Up to 5 years
|
Phase 2 Transplant-eligible cohort |
Up to 5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Clinical Trial Management, Regeneron Pharmaceuticals
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Vaatziekten
- Hart-en vaatziekten
- Neoplasmata
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Hematologische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Neoplasmata, plasmacel
- Hemostatische aandoeningen
- Paraproteïnemieën
- Bloed eiwit stoornissen
- Hemorragische aandoeningen
- Hemische en lymfatische ziekten
- Multipel myeloom
Andere studie-ID-nummers
- R5458-ONC-2158
- 2022-500800-24-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD-tijdsbestek voor delen
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-toegangscriteria voor delen
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- ANALYTIC_CODE
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .